Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

Justine R. Smith, Ralph D. Levinson, Gary N. Holland, Douglas A. Jabs, Michael R. Robinson, Scott M. Whitcup, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

276 Citations (Scopus)

Abstract

Objective. To evaluate the clinical usefulness of tumor necrosis factor (TNF) inhibitors in patients with inflammatory eye disease that is resistant to conventional immunosuppressive therapies. Methods. Sixteen patients (4 males and 12 females aged 7 to 78 years) who received etanercept (n=14) or infliximab (n=2) for either inflammatory eye disease or associated joint disease were studied retrospectively to determine the effect of these medications on their ocular inflammation. Results. Nine cases of uveitis and 7 cases of scleritis were treated. Systemic diagnoses included rheumatoid arthritis (n=8), juvenile rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), and psoriatic spondylarthropathy (n=1). Three patients had uveitis without associated systemic disease. Although 12 of 12 patients with active articular inflammation (100%) experienced improvement in joint disease, only 6 of 16 with ocular inflammation (38%) experienced improvement in eye disease. Five patients developed inflammatory eye disease for the first time while taking a TNF inhibitor. No patient discontinued treatment because of adverse drug effects. Conclusion. TNF inhibitors are well tolerated immunosuppressive medications that may benefit certain subgroups of patients with inflammatory eye disease, but they appear to be more effective in controlling associated inflammatory arthritis.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalArthritis Care and Research
Volume45
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Eye Diseases
Rheumatic Diseases
Tumor Necrosis Factor-alpha
Joint Diseases
Uveitis
Immunosuppressive Agents
Inflammation
Scleritis
Spondylarthropathies
Juvenile Arthritis
Ankylosing Spondylitis
Arthritis
Rheumatoid Arthritis
Joints
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. / Smith, Justine R.; Levinson, Ralph D.; Holland, Gary N.; Jabs, Douglas A.; Robinson, Michael R.; Whitcup, Scott M.; Rosenbaum, James (Jim).

In: Arthritis Care and Research, Vol. 45, No. 3, 2001, p. 252-257.

Research output: Contribution to journalArticle

Smith, Justine R. ; Levinson, Ralph D. ; Holland, Gary N. ; Jabs, Douglas A. ; Robinson, Michael R. ; Whitcup, Scott M. ; Rosenbaum, James (Jim). / Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. In: Arthritis Care and Research. 2001 ; Vol. 45, No. 3. pp. 252-257.
@article{6e495d85dda4433abc968e02ff219695,
title = "Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease",
abstract = "Objective. To evaluate the clinical usefulness of tumor necrosis factor (TNF) inhibitors in patients with inflammatory eye disease that is resistant to conventional immunosuppressive therapies. Methods. Sixteen patients (4 males and 12 females aged 7 to 78 years) who received etanercept (n=14) or infliximab (n=2) for either inflammatory eye disease or associated joint disease were studied retrospectively to determine the effect of these medications on their ocular inflammation. Results. Nine cases of uveitis and 7 cases of scleritis were treated. Systemic diagnoses included rheumatoid arthritis (n=8), juvenile rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), and psoriatic spondylarthropathy (n=1). Three patients had uveitis without associated systemic disease. Although 12 of 12 patients with active articular inflammation (100{\%}) experienced improvement in joint disease, only 6 of 16 with ocular inflammation (38{\%}) experienced improvement in eye disease. Five patients developed inflammatory eye disease for the first time while taking a TNF inhibitor. No patient discontinued treatment because of adverse drug effects. Conclusion. TNF inhibitors are well tolerated immunosuppressive medications that may benefit certain subgroups of patients with inflammatory eye disease, but they appear to be more effective in controlling associated inflammatory arthritis.",
author = "Smith, {Justine R.} and Levinson, {Ralph D.} and Holland, {Gary N.} and Jabs, {Douglas A.} and Robinson, {Michael R.} and Whitcup, {Scott M.} and Rosenbaum, {James (Jim)}",
year = "2001",
language = "English (US)",
volume = "45",
pages = "252--257",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

AU - Smith, Justine R.

AU - Levinson, Ralph D.

AU - Holland, Gary N.

AU - Jabs, Douglas A.

AU - Robinson, Michael R.

AU - Whitcup, Scott M.

AU - Rosenbaum, James (Jim)

PY - 2001

Y1 - 2001

N2 - Objective. To evaluate the clinical usefulness of tumor necrosis factor (TNF) inhibitors in patients with inflammatory eye disease that is resistant to conventional immunosuppressive therapies. Methods. Sixteen patients (4 males and 12 females aged 7 to 78 years) who received etanercept (n=14) or infliximab (n=2) for either inflammatory eye disease or associated joint disease were studied retrospectively to determine the effect of these medications on their ocular inflammation. Results. Nine cases of uveitis and 7 cases of scleritis were treated. Systemic diagnoses included rheumatoid arthritis (n=8), juvenile rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), and psoriatic spondylarthropathy (n=1). Three patients had uveitis without associated systemic disease. Although 12 of 12 patients with active articular inflammation (100%) experienced improvement in joint disease, only 6 of 16 with ocular inflammation (38%) experienced improvement in eye disease. Five patients developed inflammatory eye disease for the first time while taking a TNF inhibitor. No patient discontinued treatment because of adverse drug effects. Conclusion. TNF inhibitors are well tolerated immunosuppressive medications that may benefit certain subgroups of patients with inflammatory eye disease, but they appear to be more effective in controlling associated inflammatory arthritis.

AB - Objective. To evaluate the clinical usefulness of tumor necrosis factor (TNF) inhibitors in patients with inflammatory eye disease that is resistant to conventional immunosuppressive therapies. Methods. Sixteen patients (4 males and 12 females aged 7 to 78 years) who received etanercept (n=14) or infliximab (n=2) for either inflammatory eye disease or associated joint disease were studied retrospectively to determine the effect of these medications on their ocular inflammation. Results. Nine cases of uveitis and 7 cases of scleritis were treated. Systemic diagnoses included rheumatoid arthritis (n=8), juvenile rheumatoid arthritis (n=3), ankylosing spondylitis (n=1), and psoriatic spondylarthropathy (n=1). Three patients had uveitis without associated systemic disease. Although 12 of 12 patients with active articular inflammation (100%) experienced improvement in joint disease, only 6 of 16 with ocular inflammation (38%) experienced improvement in eye disease. Five patients developed inflammatory eye disease for the first time while taking a TNF inhibitor. No patient discontinued treatment because of adverse drug effects. Conclusion. TNF inhibitors are well tolerated immunosuppressive medications that may benefit certain subgroups of patients with inflammatory eye disease, but they appear to be more effective in controlling associated inflammatory arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0034796250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034796250&partnerID=8YFLogxK

M3 - Article

C2 - 11409666

AN - SCOPUS:0034796250

VL - 45

SP - 252

EP - 257

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -